メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
富山大学 ホーム
日本語
English
ホーム
プロファイル
研究部門
プロジェクト
研究成果
データセット
受賞
活動
コース
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
藤浪 斗
准教授, 博士（医学） 富山大学 2009年7月
光学医療診療部
h-index
291
被引用数
10
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2008
2025
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(22)
データセット
(4)
コース
(2)
類似のプロファイル
(6)
フィンガープリント
Haruka Fujinamiが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Keyphrases
Advanced Gastric Cancer
84%
Cisplatin
60%
Endoscopic Ultrasound-guided Fine-needle Aspiration (EUS-FNA)
53%
Gastrointestinal Stromal Tumor
50%
Docetaxel
50%
Gastric Cancer
42%
Endoscopic Submucosal Dissection
42%
Fluoropyrimidine
35%
Helicobacter Pylori (H. pylori)
35%
Shakuyakukanzoto
33%
Intra-aortic Balloon Occlusion
33%
Endoscopic Hemostasis
33%
Endoscopic Retrograde Cholangiopancreatography
33%
Jejunum
33%
Stomach
33%
Franseen Needle
33%
Infliximab
33%
Ulcer
33%
Ulcerative Colitis
33%
Median Progression-free Survival
33%
Irinotecan
32%
Chemotherapy
32%
Proton Pump Inhibitors
30%
Japan
29%
Median Overall Survival
28%
Clinical Trials
27%
Risk Factors
27%
Colorectal Cancer
27%
Diarrhea
26%
Older Men
25%
Chemotherapy-induced Diarrhea
25%
Monotherapy
25%
Amrubicin
25%
Combination Chemotherapy
24%
Inflammatory Bowel Disease
24%
Biopsy Specimen
23%
Endoscopy
22%
Pathological Diagnosis
22%
Paclitaxel
22%
Tumor
21%
KIT Gene
21%
Pancreatitis
21%
Blood Pressure
21%
Stenosis
21%
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
21%
Submucosal Tumor
21%
Acute Pancreatitis
20%
Gastrointestinal Cancer
20%
Gastrointestinal Endoscopy
20%
Warfarin
19%
Medicine and Dentistry
Abdominal Cancer
55%
Neoplasm
51%
Bleeding
49%
Endoscopic Ultrasound Guided Fine Needle Biopsy
47%
Endoscopic Submucosal Dissection
42%
Ulcer
40%
Endoscopy
39%
Diagnosis
36%
Arm
33%
Jejunum
33%
Endoscopic Ultrasound
33%
Fine-Needle Aspiration
33%
Gastrointestinal Stromal Tumor
33%
Endoscopic Retrograde Cholangiopancreatography
33%
Balloon Occlusion
33%
Endoscopic Hemostasis
33%
Randomized Controlled Trial
33%
Ulcerative Colitis
33%
Biopsy Technique
29%
Pancreas Cancer
28%
Chemotherapy
27%
Duodenum
22%
Retrospective Study
21%
Stenosis
21%
Blood Pressure
21%
Immunity
20%
Nonsteroid Antiinflammatory Agent
20%
Helicobacter Pylori
20%
Warfarin
19%
Fluoropyrimidine
19%
Gastrointestinal Endoscopy
19%
Irinotecan
18%
Antithrombotic
18%
Drug Use
18%
Total Stomach Resection
16%
Clinical Trial
16%
Nivolumab
16%
Cancer Recurrence
16%
Endoscopic Papillotomy
16%
Esophagus Tumor
16%
N [bis(1 Aziridinyl)phosphinyl] 4 Iodobenzamide
16%
Non Invasive Procedure
16%
Duodenum Motility
16%
Medicine
16%
Non Erosive Reflux Disease
16%
Mitomycin
16%
Duodenal Ulcer Bleeding
16%
Pancreatitis
16%
Interstitial Lung Disease
16%
Self-Expandable Metallic Stent
16%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Abdominal Cancer
88%
Cisplatin
57%
Docetaxel
50%
Diarrhea
39%
Overall Survival
36%
Fluoropyrimidine
36%
Progression Free Survival
34%
Paclitaxel
33%
Neuroendocrine Carcinoma
33%
Infliximab
33%
Clinical Trial
27%
Irinotecan
26%
Inflammatory Bowel Disease
24%
Acute Pancreatitis
21%
Constipation
21%
Adverse Event
20%
Monotherapy
20%
Amrubicin
20%
Pancreatitis
19%
Fluorouracil
19%
Injury
19%
Crohn's Disease
16%
Mitomycin
16%
Immunoglobulin A
16%
Stag
16%
Mercaptopurine
16%
Tumor Necrosis Factor Inhibitor
16%
Digestive System Cancer
16%
Vasculitis
16%
Pancreas Cancer
16%
Citrullinemia Type II
16%
Esophageal Squamous Cell Carcinoma
16%
Protein Losing Gastroenteropathy
16%
Down Syndrome
16%
Lafutidine
16%
Rabeprazole
16%
Amoxicillin
16%
Helicobacter Pylori
16%
Esophagus Tumor
16%
Nedaplatin
16%
Anticoagulant Agent
16%
Metronidazole
16%
Cytokine
16%
Carcinogenesis
16%
Ramucirumab
16%
Lupus Vulgaris
16%
Koji
16%
Antihypertensive
16%
Ulcerative Colitis
16%
